Given their small size, the use of adjuvants along with target antigens help in their successful delivery to antigen presenting cells. A closer look at our data indicates that the number of publications related to cancer vaccines in immunotherapy have grown at a modest rate over 2020-2022 (Figs. and). Amongst the various types of cancer vaccines, RNA-based and nanovaccines have grown the fastest in the last three years (Fig. ).